Published in Br J Dermatol on May 01, 2004
Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med (2005) 4.04
Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med (2009) 2.82
Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One (2010) 1.73
Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon (2011) 1.59
Lymphocyte subsets in peripheral blood of patients with moderate-to-severe versus mild plaque psoriasis. Arch Dermatol Res (2007) 1.47
Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol (2007) 1.41
Human natural killer T cells infiltrate into the skin at elicitation sites of allergic contact dermatitis. J Invest Dermatol (2007) 1.08
Activation of keratinocyte protein kinase C zeta in psoriasis plaques. J Invest Dermatol (2008) 1.02
Interleukin-1 regulates keratinocyte expression of T cell targeting chemokines through interleukin-1 receptor associated kinase-1 (IRAK1) dependent and independent pathways. Cell Signal (2009) 1.00
Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)/IgG1 fusion protein alefacept. Clin Exp Immunol (2007) 0.92
Integrated network analysis of transcriptomic and proteomic data in psoriasis. BMC Syst Biol (2010) 0.91
Use of Kv1.3 blockers for inflammatory skin conditions. Curr Med Chem (2010) 0.80
Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model. J Autoimmun (2014) 0.79
Rise in dermal CD11c+ dendritic cells associates with early-stage development of psoriatic lesions. Arch Dermatol Res (2012) 0.79
N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3. FEBS J (2015) 0.78
Role of CD4CD25FOXP3 Regulatory T Cells in Psoriasis. Ann Dermatol (2010) 0.78
Diagnostic utility of Ki-67 and Cyclin D1 immunostaining in differentiation of psoriasis vs. other psoriasiform dermatitis. Dermatol Pract Concept (2015) 0.75
A Case of Severe HIV-Associated Psoriasis Successfully Treated with Acitretin Therapy. Infect Chemother (2014) 0.75
Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy. Dermatology (2008) 1.82
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol (2005) 1.72
Management of palmoplantar pustulosis: do we need to change? Br J Dermatol (2011) 1.49
Lymphocyte subsets in peripheral blood of patients with moderate-to-severe versus mild plaque psoriasis. Arch Dermatol Res (2007) 1.47
A di-leucine motif and an upstream serine in the interleukin-6 (IL-6) signal transducer gp130 mediate ligand-induced endocytosis and down-regulation of the IL-6 receptor. J Biol Chem (1996) 1.47
Narrowband ultraviolet B therapy in psoriasis: randomized double-blind comparison of high-dose and low-dose irradiation regimens. Br J Dermatol (2009) 1.41
The Impact of Chronic Skin Disease on Daily Life (ISDL): a generic and dermatology-specific health instrument. Br J Dermatol (2007) 1.40
Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with paediatric- or adult-onset disease. Br J Dermatol (2015) 1.40
The effectiveness and safety of short-contact dithranol therapy in paediatric psoriasis: a prospective comparison of regular day care and day care with telemedicine. Br J Dermatol (2014) 1.39
Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumab. Br J Dermatol (2011) 1.39
European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol (2006) 1.30
Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br J Dermatol (2006) 1.29
Immunohistochemical differentiation between inflammatory linear verrucous epidermal nevus (ILVEN) and psoriasis. Eur J Dermatol (2004) 1.19
Expression of the extracellular matrix proteins collagen I, collagen III and fibronectin and matrix metalloproteinase-1 and -13 in the skin of patients with inguinal hernia. Eur Surg Res (1999) 1.08
How stress gets under the skin: cortisol and stress reactivity in psoriasis. Br J Dermatol (2010) 1.05
Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis. Br J Dermatol (2005) 1.02
Internalization of the interleukin 6 signal transducer gp130 does not require activation of the Jak/STAT pathway. Biochem J (1998) 0.97
Individual differences in the effect of daily stressors on psoriasis: a prospective study. Br J Dermatol (2009) 0.97
Prevalence of physical symptoms of itch, pain and fatigue in patients with skin diseases in general practice. Br J Dermatol (2007) 0.96
The prevalence of onychomycosis in psoriatic patients: a systematic review. J Eur Acad Dermatol Venereol (2013) 0.93
Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol (2008) 0.89
Paediatric-onset psoriasis is associated with ERAP1 and IL23R loci, LCE3C_LCE3B deletion and HLA-C*06. Br J Dermatol (2012) 0.88
Identification of lesional CD4+ CD25+ Foxp3+ regulatory T cells in Psoriasis. Dermatology (2006) 0.88
Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Dermatol Venereol (2006) 0.87
Treatment of vitiligo vulgaris with narrow band UVB (311 nm) for one year and the effect of addition of folic acid and vitamin B12. Acta Derm Venereol (2002) 0.87
Psychosocial well-being of patients with skin diseases in general practice. J Eur Acad Dermatol Venereol (2007) 0.87
Quality of life and sexual health in patients with genital psoriasis. Br J Dermatol (2011) 0.86
Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. Aliment Pharmacol Ther (2006) 0.86
The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. Exp Dermatol (2004) 0.86
'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network. Br J Dermatol (2014) 0.86
Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis. Br J Dermatol (2014) 0.86
Reflectance confocal microscopy: an effective tool for monitoring ultraviolet B phototherapy in psoriasis. Br J Dermatol (2012) 0.85
Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol (2012) 0.85
Cellular features of psoriatic skin: imaging and quantification using in vivo reflectance confocal microscopy. Cytometry B Clin Cytom (2010) 0.84
A placebo-controlled randomized study on the clinical effectiveness, immunohistochemical changes and protoporphyrin IX accumulation in fractionated 5-aminolaevulinic acid-photodynamic therapy in patients with psoriasis. Br J Dermatol (2006) 0.84
Increased incidence of squamous cell carcinoma of the skin after long-term treatment with azathioprine in patients with auto-immune inflammatory rheumatic diseases. J Eur Acad Dermatol Venereol (2012) 0.84
Heterogeneity of fluorescence in psoriasis after application of 5-aminolaevulinic acid: an immunohistochemical study. Br J Dermatol (2006) 0.84
Etanercept combined with methotrexate for high-need psoriasis. Br J Dermatol (2008) 0.84
Balance of Treg vs. T-helper cells in the transition from symptomless to lesional psoriatic skin. Br J Dermatol (2013) 0.84
Genital psoriasis: a questionnaire-based survey on a concealed skin disease in the Netherlands. J Eur Acad Dermatol Venereol (2010) 0.83
The differential effect of broad band vs narrow band UVB with respect to photodamage and cutaneous inflammation. Exp Dermatol (2003) 0.83
Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin. J Am Acad Dermatol (2003) 0.83
Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network. Br J Dermatol (2014) 0.82
Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome. Br J Dermatol (2008) 0.82
The psychophysiological stress response in psoriasis and rheumatoid arthritis. Br J Dermatol (2014) 0.82
An intrapatient comparison of quality of life in psoriasis in childhood and adulthood. J Eur Acad Dermatol Venereol (2010) 0.82
Topical treatment of mild to moderate plaque psoriasis with 0.3% tacrolimus gel and 0.5% tacrolimus cream: the effect on SUM score, epidermal proliferation, keratinization, T-cell subsets and HLA-DR expression. Br J Dermatol (2008) 0.82
Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry. J Eur Acad Dermatol Venereol (2014) 0.82
Juvenile psoriasis in European and Asian children: similarities and differences. Br J Dermatol (2011) 0.81
Oral retinoic acid metabolism blocking agent Rambazole for plaque psoriasis: an immunohistochemical study. Br J Dermatol (2007) 0.81
Immunofluorescent surface labelling, flow sorting and culturing of putative epidermal stem cells derived from small skin punch biopsies. J Immunol Methods (2002) 0.81
Combinations of classical time-honoured topicals in plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol (2012) 0.81
Safety of treatment with biologics for psoriasis in daily practice: 5-year data. J Eur Acad Dermatol Venereol (2011) 0.81
Expression of heat shock protein 70 (HSP70) at the interface of polymer-implants in vivo. J Mater Sci Mater Med (2000) 0.80
Assessment of epidermal subpopulations and proliferation in healthy skin, symptomless and lesional skin of spreading psoriasis. Br J Dermatol (2006) 0.80
Nail Psoriasis, the unknown burden of disease. J Eur Acad Dermatol Venereol (2014) 0.80
Role of induced negative and positive emotions in sensitivity to itch and pain in women. Br J Dermatol (2012) 0.80
A framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol Venereol (2012) 0.80
Efficacy of blue light vs. red light in the treatment of psoriasis: a double-blind, randomized comparative study. J Eur Acad Dermatol Venereol (2011) 0.80
Application of leukotriene B4 and reflectance confocal microscopy as a noninvasive in vivo model to study the dynamics of skin inflammation. Skin Res Technol (2014) 0.80
A multiparameter flow cytometric analysis of the effect of bexarotene on the epidermis of the psoriatic lesion. Br J Dermatol (2003) 0.80
Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. Br J Dermatol (2010) 0.80
Debilitating consequences of drooling. J Neurol (2009) 0.80
Comparing treatment goals for psoriasis with treatment decisions in daily practice: results from a prospective cohort of patients with psoriasis treated with biologics: BioCAPTURE. Br J Dermatol (2014) 0.80
A cross-sectional study using the Children's Dermatology Life Quality Index (CDLQI) in childhood psoriasis: negative effect on quality of life and moderate correlation of CDLQI with severity scores. Br J Dermatol (2010) 0.80
No evidence found that childhood onset of psoriasis influences disease severity, future body mass index or type of treatments used. J Eur Acad Dermatol Venereol (2010) 0.79
A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting. Br J Dermatol (2007) 0.79
Tacrolimus ointment for the treatment of severe facial plaque psoriasis. J Eur Acad Dermatol Venereol (2005) 0.79
An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors. J Eur Acad Dermatol Venereol (2014) 0.78
Aggravation of psoriasis by infections: a constitutional trait or a variable expression? Eur J Dermatol (2004) 0.78
New developments in our understanding of psoriatic arthritis and their impact on the diagnosis and clinical management of the disease. J Eur Acad Dermatol Venereol (2013) 0.78
Summary of the Dutch S3-guidelines on the treatment of psoriasis 2011. Dutch Society of Dermatology and Venereology. Dermatol Online J (2014) 0.78
Induction of protoporphyrin IX by aminolaevulinic acid in actinic keratosis, psoriasis and normal skin: preferential porphyrin enrichment in differentiated cells. Br J Dermatol (2009) 0.78
Nail psoriasis: a questionnaire-based survey. Br J Dermatol (2013) 0.78
Monitoring hyperproliferative disorders in human skin: flow cytometry of changing cytokeratin expression. Cytometry B Clin Cytom (2004) 0.78
CD26/dipeptidyl-peptidase IV in psoriatic skin: upregulation and topographical changes. Br J Dermatol (2008) 0.78
Infrared densitometry: a fast and non-destructive method for exact stratum corneum depth calculation for in vitro tape-stripping. Skin Pharmacol Physiol (2010) 0.77
Generalized and symptom-specific sensitization of chronic itch and pain. J Eur Acad Dermatol Venereol (2007) 0.77
Flexural versus plaque lesions in psoriasis: an immunohistochemical differentiation. Eur J Dermatol (2005) 0.77
Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper. J Dermatolog Treat (2014) 0.77
Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients. J Eur Acad Dermatol Venereol (2012) 0.77
Efficacy of the pulsed dye laser in the treatment of localized recalcitrant plaque psoriasis: a comparative study. Br J Dermatol (2006) 0.77
Oral R115866 in the treatment of moderate to severe plaque-type psoriasis. J Eur Acad Dermatol Venereol (2007) 0.77
Calcipotriol/betamethasone dipropionate ointment in mild-to-moderate paediatric psoriasis: long-term daily clinical practice data in a prospective cohort. Br J Dermatol (2014) 0.76
Distribution of dipeptidyl-peptidase IV on keratinocytes in the margin zone of a psoriatic lesion: a comparison with hyperproliferation and aberrant differentiation markers. Arch Dermatol Res (2008) 0.76
Cervicovaginal HPV infection in female renal transplant recipients: an observational, self-sampling based, cohort study. Am J Transplant (2015) 0.76
Dithranol therapy in childhood psoriasis: unjustifiably on the verge of falling into oblivion. Dermatology (2010) 0.76
Combining lesional short-contact dithranol therapy of psoriasis with a potent topical corticosteroid. Br J Dermatol (2002) 0.76
Systemic treatments in paediatric psoriasis: a systematic evidence-based update. J Eur Acad Dermatol Venereol (2014) 0.76
The influence of treatments in daily clinical practice on the Children's Dermatology Life Quality Index in juvenile psoriasis: a longitudinal study from the Child-CAPTURE patient registry. Br J Dermatol (2012) 0.76
Alefacept modifies long-term disease severity and improves the response to other treatments. Eur J Dermatol (2005) 0.76
The effect of alefacept on T-cell subsets and cells expressing NK receptors in lesional psoriatic skin: the effects of monotherapy and combination treatment with calcipotriol. J Dermatolog Treat (2008) 0.76
Period of remission after treatment with UVA-1 in sclerodermic skin diseases. J Eur Acad Dermatol Venereol (2008) 0.76
Sedentary patients with venous or mixed leg ulcers: determinants of physical activity. J Adv Nurs (2007) 0.75
Once daily vs. twice daily applications of topical treatments in psoriasis. Br J Dermatol (2005) 0.75
The effect of the PDE-4 inhibitor (cipamfylline) in two human models of irritant contact dermatitis. Arch Dermatol Res (2003) 0.75
Cutaneous application of leukotriene B4 as an in vivo model of psoriasis-like skin inflammation: an immunohistological study. Skin Pharmacol Physiol (2014) 0.75